SCHEMBL3974252

SCHEMBL3974252

Cn1cccc1CN1CCCC1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
ALDH1A1 P00352 3/20 0.49
KDM4E B2RXH2 2/20 0.49
MAOB P27338 2/20 0.47
HRH3 Q9Y5N1 2/20 0.43
MBTD1 Q05BQ5 1/20 0.41
L3MBTL3 Q96JM7 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
PARP1 P09874 1/20 0.41
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
HRH4 Q9H3N8 1/20 0.39
NCF1 P14598 1/20 0.39
SLC6A3 Q01959 1/20 0.38
PRMT6 Q96LA8 1/20 0.38
CHRNB2 P17787 1/20 0.38
CHRNA4 P43681 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2964590 0.98 MAOB (0.50) MEN1KMT2AALDH1A1KDM4EMAOB
SCHEMBL3975479 0.98 MAOB (0.50) MEN1KMT2AALDH1A1KDM4EMAOB
SCHEMBL2979758 0.86 MC4R (0.53) MEN1KMT2AALDH1A1KDM4EPARP1
SCHEMBL28842755 0.83 CYP2A13 (0.49) MEN1KMT2AALDH1A1KDM4EHRH3
SCHEMBL2995258 0.83 MEN1 (0.41) MEN1KMT2AALDH1A1KDM4EMAOB
SCHEMBL15471355 0.82 MEN1 (0.44) MEN1KMT2AALDH1A1KDM4EMAOB
SCHEMBL14375356 0.82 ACHE (0.54) MEN1KMT2AALDH1A1KDM4EHRH3
SCHEMBL17968032 0.80 PARP1 (0.47) MEN1KMT2AALDH1A1KDM4EPARP1
SCHEMBL13003775 0.80 MEN1 (0.48) MEN1KMT2AALDH1A1KDM4EPARP1
SCHEMBL16026534 0.80 MEN1 (0.48) MEN1KMT2AALDH1A1KDM4EMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010077976-A2 PROKINETICIN RECEPTOR ANTAGONISTS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-07-08 WO disclosed
US-7547790-B2 Optically active 4,4-di-substituted oxazolidine derivative and method for producing same SANKYO COMPANY, LIMITED (JP) 2009-06-16 US disclosed
US-20080108828-A1 Optically Active 4,4-Di-Substituted Oxazolidine Derivative and Method for Producing Same SANKYO COMPANY, LIMITED (JP) 2008-05-08 US disclosed
EP-1806344-A1 OPTICALLY ACTIVE 4,4-DISUBSTITUTED OXAZOLIDINE DERIVATIVE AND METHOD FOR PRODUCING SAME Sankyo Company, Limited (JP) 2007-07-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108828-A1 Optically Active 4,4-Di-Substituted Oxazolidine Derivative and Method for Producing Same CBR3, C9, COX6C MEN1 1770/4885KMT2A 1201/4885ALDH1A1 1247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.